Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes - PubMed (original) (raw)
Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes
Kenji Kawada et al. Cancer Res. 2004.
Abstract
Chemokines and their receptors play key roles in leukocyte trafficking and are also implicated in cancer metastasis to specific organs. Here we show that mouse B16F10 melanoma cells constitutively express chemokine receptor CXCR3, and that its ligands CXCL9/Mig, CXCL10/IP-10, and CXCL11/I-TAC induce cellular responses in vitro, such as actin polymerization, migration, invasion, and cell survival. To determine whether CXCR3 could play a role in metastasis to lymph nodes (LNs), we constructed B16F10 cells with reduced CXCR3 expression by antisense RNA and investigated their metastatic activities after s.c. inoculations to syngeneic hosts, C57BL/6 mice. The metastatic frequency of these cells to LNs was markedly reduced to approximately 15% (P < 0.05) compared with the parental or empty vector-transduced cells. On the other hand, pretreatment of mice with complete Freund's adjuvant increased the levels of CXCL9 and CXCL10 in the draining LNs, which caused 2.5-3.0-fold increase (P < 0.05) in the metastatic frequency of B16F10 cells to the nodes with much larger foci. Importantly, such a stimulation of metastasis was largely suppressed when CXCR3 expression in B16F10 cells was reduced by antisense RNA or when mice were treated with specific antibodies against CXCL9 and CXCL10. We also demonstrate that CXCR3 is expressed on several human melanoma cell lines as well as primary human melanoma tissues (5 of 9 samples tested). These results suggest that CXCR3 inhibitors may be promising therapeutic agents for treatment of LN metastasis, including that of melanoma.
Similar articles
- Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes.
Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y, Sakai Y, Takabayashi A, Oshima M, Taketo MM. Kawada K, et al. Oncogene. 2007 Jul 12;26(32):4679-88. doi: 10.1038/sj.onc.1210267. Epub 2007 Feb 5. Oncogene. 2007. PMID: 17297455 - CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.
Zipin-Roitman A, Meshel T, Sagi-Assif O, Shalmon B, Avivi C, Pfeffer RM, Witz IP, Ben-Baruch A. Zipin-Roitman A, et al. Cancer Res. 2007 Apr 1;67(7):3396-405. doi: 10.1158/0008-5472.CAN-06-3087. Cancer Res. 2007. PMID: 17409450 - Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis.
Narumi S, Kaburaki T, Yoneyama H, Iwamura H, Kobayashi Y, Matsushima K. Narumi S, et al. Eur J Immunol. 2002 Jun;32(6):1784-91. doi: 10.1002/1521-4141(200206)32:6<1784::AID-IMMU1784>3.0.CO;2-R. Eur J Immunol. 2002. PMID: 12115662 - Chemokine receptor CXCR3: an unexpected enigma.
Liu L, Callahan MK, Huang D, Ransohoff RM. Liu L, et al. Curr Top Dev Biol. 2005;68:149-81. doi: 10.1016/S0070-2153(05)68006-4. Curr Top Dev Biol. 2005. PMID: 16124999 Review. - CXCR3 axis: role in inflammatory bowel disease and its therapeutic implication.
Singh UP, Venkataraman C, Singh R, Lillard JW Jr. Singh UP, et al. Endocr Metab Immune Disord Drug Targets. 2007 Jun;7(2):111-23. doi: 10.2174/187153007780832109. Endocr Metab Immune Disord Drug Targets. 2007. PMID: 17584151 Review.
Cited by
- Neutralizing nanobodies targeting diverse chemokines effectively inhibit chemokine function.
Blanchetot C, Verzijl D, Mujić-Delić A, Bosch L, Rem L, Leurs R, Verrips CT, Saunders M, de Haard H, Smit MJ. Blanchetot C, et al. J Biol Chem. 2013 Aug 30;288(35):25173-25182. doi: 10.1074/jbc.M113.467969. Epub 2013 Jul 8. J Biol Chem. 2013. PMID: 23836909 Free PMC article. - Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis.
Hu Z, Brooks SA, Dormoy V, Hsu CW, Hsu HY, Lin LT, Massfelder T, Rathmell WK, Xia M, Al-Mulla F, Al-Temaimi R, Amedei A, Brown DG, Prudhomme KR, Colacci A, Hamid RA, Mondello C, Raju J, Ryan EP, Woodrick J, Scovassi AI, Singh N, Vaccari M, Roy R, Forte S, Memeo L, Salem HK, Lowe L, Jensen L, Bisson WH, Kleinstreuer N. Hu Z, et al. Carcinogenesis. 2015 Jun;36 Suppl 1(Suppl 1):S184-202. doi: 10.1093/carcin/bgv036. Carcinogenesis. 2015. PMID: 26106137 Free PMC article. Review. - Impaired CXCL4 expression in tumor-associated macrophages (TAMs) of ovarian cancers arising in endometriosis.
Furuya M, Tanaka R, Miyagi E, Kami D, Nagahama K, Miyagi Y, Nagashima Y, Hirahara F, Inayama Y, Aoki I. Furuya M, et al. Cancer Biol Ther. 2012 Jun;13(8):671-80. doi: 10.4161/cbt.20084. Epub 2012 Jun 1. Cancer Biol Ther. 2012. PMID: 22555803 Free PMC article. - Cytokines, chemokines, and chemokine receptors quantitative expressions in patients with ovarian cancer.
Rezaeifard S, Razmkhah M, Robati M, Momtahan M, Ghaderi A. Rezaeifard S, et al. Iran J Med Sci. 2015 May;40(3):225-32. Iran J Med Sci. 2015. PMID: 25999622 Free PMC article. - Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers.
Jacquelot N, Duong CPM, Belz GT, Zitvogel L. Jacquelot N, et al. Front Immunol. 2018 Oct 29;9:2480. doi: 10.3389/fimmu.2018.02480. eCollection 2018. Front Immunol. 2018. PMID: 30420855 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials